Phase I study of bryostatin-1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma

Clinical Lymphoma

Volumn 3, Issue 3, 2002, Pages 184-188

  Roberts, John D ^a   Smith, Mitchell R ^b   Feldman, Eric J ^c   Cragg, Louise ^d   Grant, Steven ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d Interventional Radiology Section of Radiologists of North Iowa   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; BRYOSTATIN 1; CLADRIBINE; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GAMMA INTERFERON; IBRITUMOMAB TIUXETAN; LACTATE DEHYDROGENASE; METHOTREXATE; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; PLATINUM; PREDNISONE; PROTEIN BCL 2; PROTEIN KINASE C; PURINE NUCLEOSIDE DERIVATIVE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; URIC ACID; VINCRISTINE;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CELL ACTIVATION; CELL DIFFERENTIATION; CELL STIMULATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENTIATION; FATIGUE; HUMAN; INFECTION; LYMPHOCYTOPENIA; MYALGIA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHLEBITIS; THROMBOCYTE AGGREGATION; VOMITING;

EID: 0036954116     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2002.n.025     Document Type: Article

References (39)

1. Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000; 96:2723-2729.
2. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343:1750-1757.
3. Johnson S, Smith AG, Loffler H, et al. Multi-centre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996; 347:1432-1438.
4. Mutter R, Wills M. Chemistry and clinical biology of the bryostatins. Bioorg Med Chem 2000; 8:1841-1860.
5. Hornung RL, Pearson JW, Beckwith M, et al. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res 1992; 52:101-107.
6. Kennedy MJ, Prestigiacomo LJ, Tyler G, et al. Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. Cancer Res 1992; 52:1278-1283.
7. Drexler HG, Gignac SM, Jones RA, et al. Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells. Blood 1989; 74:1747-1757.
8. May WS, Sharkis SJ, Esa AH, et al. Antineoplastic bryostatins are mithipotential stimulators of human hematopoietic progenitor cells. Proc Natl Acad Sci U S A 1987; 84:8483-8487.
9. Tallant EA, Smith JB, Wallace RW. Bryostatins mimic the effects of phorbol esters in intact human platelets. Biochim Biophys Acta 1987; 929:40-46.
10. Berkow RL, Kraft AS. Bryostatin, a non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor. Biochem Biophys Res Commun 1985; 131:1109-1116.
11. Bosco MC, Rottschafer S, Taylor LS, et al. The antineoplastic agent bryostatin-1 induces proinflammatory cytokine production in human monocytes: synergy with interleukin-2 and modulation of interleukin-2Rgamma chain expression. Blood 1997; 89:3402-3411.
12. Hess AD, Silanskis MK, Esa AH, et al. Activation of human T lymphocytes by bryostatin. J Immunol 1988; 141:3263-3269.
13. McCrady CW, Staniswalis J, Pettit GR, et al. Effect of pharmacologic manipulation of protein kinase C by phorbol dibutyrate and bryostatin 1 on the clonogenic response of human granulocyte-macrophage progenitors to recombinant GM-CSF. Br J Haematol 1991; 77:5-15.
14. Li F, Grant S, Pettit GR, et al. Bryostatin 1 modulates the proliferation and lineage commitment of human myeloid progenitor cells exposed to recombinant interleukin-3 and recombinant granulocyte-macrophage colony-stimulating factor. Blood 1992; 80:2495-2502.
15. Grant S, Pettit GR, Howe C, et al. Effect of the protein kinase C activating agent bryostatin 1 on the clonogenic response of leukemic blast progenitors to recombinant granulocyte-macrophage colony-stimulating factor. Leukemia 1991; 5:392-398.
16. Grant S, Traylor R, Bhalla K, et al. Effect of a combined exposure to cytosine arabinoside, bryostatin 1, and recombinant granulocyte-macrophage colony-stimulating factor on the clonogenic growth in vitro of normal and leukemic human hematopoietic progenitor cells. Leukemia 1992; 6:432-439.
17. Bhatia U, Traganos F, Darzynkiewicz Z. Induction of cell differentiation potentiates apoptosis triggered by prior exposure to DNA-damaging drugs. Cell Growth Differ 1995; 6:937-944.
18. Vrana JA, Wang Z, Rao AS, et al. Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): interactions with the macrocyclic lactone bryostatin 1. Leukemia 1999; 13:1046-1055.
19. Mohammad RM, Katato K, Almatchy VP, et al. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies. Clin Cancer Res 1998; 4:445-453.
20. Mohammad RM, Limvarapuss C, Hamdy N, et al. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine. Int J Oncol 1999; 14:945-950.
21. Goekjian PG, Jirousek MR. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs 2001; 10:2117-2140.
22. Lee HW Smith L, Pettit GR, et al. Bryostatin 1 and phorbol ester down-modulate protein kinase C-alpha and -epsilon via the ubiquitin/proteasome pathway in human fibroblasts. Mol Pharmacol 1997; 51:439-447.
23. Al-Katib AM, Smith MR, Kamanda WS, et al. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res 1998; 4:1305-1314.
24. Curiel RE, Garcia CS, Farooq L, et al. Bryostatin-1 and IL-2 synergize to induce IFN-gamma expression in human peripheral blood T cells: implication for cancer immunotherapy. J Immunol 2001; 167:4828-4837.
25. Steube KG, Drexler HG. The protein kinase C activator Bryostatin-1 induces the rapid release of TNF alpha from MONO-MAC-6 cells. Biochem Biophys Res Common 1995; 214:1197-1203.
26. Wall NR, Mohammad RM, Reddy KB, et al. Bryostatin 1 induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line, Reh. Int J Mol Med 2000; 5:165-171.
27. Prendiville J, Crowther D, Thatcher N, et al. A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 1993;68:418-424.
28. Philip PA, Rea D, Thavasu P, et al. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst 1993; 85:1812-1818.
29. Jayson GC, Crowther D, Prendiville J, et al. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer 1995; 72:461-468.
30. Varterasian ML, Mohammad RM, Eilender DS, et al. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol 1998; 16:56-62.
31. Varterasian ML, Mohammad RM, Shurafa MS, et al. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Cancer Res 2000; 6:825-828.
32. Blackhall FH, Ranson M, Radford JA, et al. A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. Br J Cancer 2001; 84:465-469.
33. Pagliaro L, Daliani D, Amato R, et al. A phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer 2000; 89:615-618.
34. Varterasian ML, Pemberton PA, Hulburd K, et al. Phase II study of bryostatin 1 in patients with relapsed multiple myeloma. Invest New Drugs 2001; 19:245-247.
35. Bedikian AY, Plager C, Stewart JR, et al. Phase II evaluation of bryostatin-1 in metastatic melanoma. Melanoma Res 2001; 11:183-188.
36. Zonder JA, Shields AF, Zalupski M, et al. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer. Clin Cancer Res 2001; 7:38-42.
37. Brockstein B, Samuels B, Humerickhouse R, et al. Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer. Invest New Drugs 2001; 19:249-254.
38. Gonzalez R, Ebbinghaus S, Henthorn TK, et al. Treatment of patients with metastatic melanoma with bryostatin-1--a phase II study. Melanoma Res 1999; 9:599-606.
39. Propper DJ, Macaulay V, O'Byrne KJ, et al. A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer 1998; 78:1337-1341.